Sign in
CompletedPhase 3

A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

Key facts

Who runs it
University of Oxford
Where
Burkina Faso, Congo - Kinshasa, Gambia, Guinea, Niger, Nigeria, Rwanda, and Tanzania8 sites in 8 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
2,583 people enrolled
Started
1 Sept 2020
Ended
15 Mar 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Artemether-lumefantrine+ Amodiaquine (AL+AQ)
  • Artemether-lumefantrine + placebo (AL+PBO)
  • Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
  • Artesunate-mefloquine+placebo (AS-MQ+PBO)
Record updated
18 November 2025

Who can take part

Age
6 months to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Male or female, aged ≥6 months to <12 years (For Gambia, Rwanda sites only: ≥6 months)
  • Ability to take oral medication
  • Acute uncomplicated P. falciparum monoinfection
  • Asexual P. falciparum parasitaemia: 1,000/µL to ≤10% parasitaemia, determined on a peripheral blood film (At Gambia, Rwanda sites only: For subjects ≥12 years - 1000/µL to 200,000/µL)
  • Fever defined as ≥ 37.5°C tympanic temperature or a history of fever within the last 24 hours
  • Written informed consent by the subject or by parent/guardian in case of children lower than the age of consent and assent if required (per local regulations)
  • Willingness and ability of the subjects or parents/guardians to comply with the study protocol for the duration of the study

Who cannot take part

  • Subjects who have received artemisinin or a derivative within the previous 7 days OR lumefantrine or amodiaquine within the previous 14 days OR mefloquine or piperaquine within the previous 30 days
  • Previous splenectomy
  • Enrolment in DeTACT in the previous 3 months
  • Participation in another interventional study in the previous 3 months
  • Acute illness other than malaria requiring systemic treatment
  • Known HIV infection
  • Known tuberculosis infection
  • History of allergy or known contraindication to any of the study drugs, including neuropsychiatric disorders and epilepsy
  • Haematocrit <15% at screening (For Gambia, Rwanda sites only: For subjects ≥12 years - Haematocrit <20% at screening)
  • Signs of severe malaria (adapted from WHO criteria)
  • Patients not fulfilling criteria for severe malaria but with another indication for parenteral antimalarial treatment at the discretion of the treating physician
  • In applicable countries: use of seasonal malaria chemoprophylaxis (SMC) within the last 14 days
  • Severe acute malnutrition (in Niger only - only those patients with Severe Acute Malnutrition and complications requiring inpatient nutritional treatment will be excluded)
  • For females: post-menarche (For Gambia, Rwanda sites only: females who are pregnant, trying to get pregnant or are lactating)

Where is this trial?

It has sites in 8 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the ACTs artemether-lumefantrine+placebo (AL+PBO), artesunate-mefloquine+placebo (ASMQ+PBO) (with single-low dose primaquine in some sites) for the treatment of uncomplicated Plasmodium falciparum malaria to assess and compare their efficacy, safety, tolerability.

The 4 groups in the trial

  • Artemether-lumefantrine+amodiaquine (AL+AQ)Treatment being tested

    Triple ACTs

  • artemether-lumefantrine+placebo (AL+PBO)Existing treatment, for comparison

    ACTs

  • Artesunate-mefloquine+Piperaquine (AS-MQ+PPQ)Treatment being tested

    Triple ACTs

  • Artesunate-mefloquine+placebo (AS-MQ+PBO)Existing treatment, for comparison

    ACTs

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-centre Randomised Controlled Non-inferiority Trial to Compare the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies Versus First-line ACTs + Placebo for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Africa
Record updated
18 November 2025